System and method for magnifying a humoral immune response

1 . A method, comprising:

delivering a treatment to a host wherein the treatment is associated with modulating a predicted pattern of progression of one or more computable epitopes.

2 . The method of claim 1 , wherein the treatment further comprises:

delivering a treatment of at least a part of one or more of a macrophage, a neutrophil, a cytotoxic cell, a lymphocyte, a T-lymphocyte, a killer T-lymphocyte, an immune response modulator, a helper T-lymphocyte, an antigen receptor, an antigen-presenting cell, a dendritic cell, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a cluster differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

3 . The method of claim 1 , wherein the treatment further comprises:

delivering a treatment of one or more modulators of at least a part of at least one of a macrophage, a neutrophil, a cytotoxic cell, a lymphocyte, a T-lymphocyte, a killer T-lymphocyte, an immune response modulator, a helper T-lymphocyte, an antigen receptor, an antigen-presenting cell, a dendritic cell, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a cluster differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

4 . The method of claim 1 , wherein the treatment further comprises:

delivering a treatment of at least a part of a B-lymphocyte.

5 . The method of claim 1 , wherein the treatment further comprises:

delivering a treatment of at least one modulator of at least a part of a B-lymphocyte.

6 . The method of claim 1 , wherein the treatment further comprises:

delivering a treatment of at least a part of at least one of an antibody, a recombinant antibody, a genetically engineered antibody, a chimeric antibody, a monospecific antibody, a bispecific antibody, a multispecific antibody, a diabody, a humanized antibody, a human antibody, a heteroantibody, a monoclonal antibody, a polyclonal antibody, a camelized antibody, a deimmunized antibody, an anti-idiotypic antibody, or an antibody fragment.

7 . The method of claim 1 , wherein the treatment further comprises:

delivering a treatment of one or more modulators of at least a part of at least one of an antibody, a recombinant antibody, a genetically engineered antibody, a chimeric antibody, a monospecific antibody, a bispecific antibody, a multispecific antibody, a diabody, a humanized antibody, a human antibody, a heteroantibody, a monoclonal antibody, a polyclonal antibody, a camelized antibody, a deimmunized antibody, an anti-idiotypic antibody, or an antibody fragment.

8 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering the treatment by at least one of a sub-cutaneous route, a nasal route, an intranasal route, an intramuscular route, an intravenous route, an intraarterial route, an intrathecal route, an intracapsular route, an intraorbital route, an intracardiac route, a transdermal route, a subdermal route, an intradermal route, an intraperitoneal route, a transtracheal route, a subcuticular route, an intraarticular route, a subcapsular route, a subarachnoidal route, an intraspinal route, an epidural route, an intrasternal route, an infusion route, a topical route, a sublingual route, or an enteric route.

9 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a part of at least one of a synthetic antibody or a modulator of a synthetic antibody.

10 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a part of a Fab region.

11 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a part of a Fab′ region.

12 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a part of a Fv region.

13 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a F(ab′).sub.2 fragment.

14 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a paratope.

15 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a portion of an antibody operable for activating at least part of a complement.

16 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a portion of an antibody operable for mediating an antibody-dependent cellular cytotoxicity.

17 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment including at least a portion of a species-dependent antibody or a species-specific antibody.

18 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment directed to an extracellular molecule.

19 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment directed to at least one of a cell-surface molecule or a cell-associated molecule.

20 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment directed to at least one of a secreted protein, a polypeptide, a glycoprotein, a receptor, and/or a receptor-ligand.

21 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment for binding at least a part of at least one antibody.

22 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent.

23 . The method of claim 22 , wherein the delivering a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent includes:

at least one suppressor of mutational alteration of the at least one agent.

24 . The method of claim 22 , wherein the delivering a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent includes:

at least one interfering nucleic acid or nucleic acid sequence.

25 . The method of claim 1 , wherein the delivering a treatment to a host further comprises:

delivering a treatment associated with modulating at least one meta-signature.

26 . (canceled)

27 . (canceled)

28 . (canceled)

29 . (canceled)

30 . (canceled)

31 . (canceled)

32 . (canceled)

33 . (canceled)

34 . (canceled)

35 . (canceled)

36 . (canceled)

37 . (canceled)

38 . (canceled)

39 . (canceled)

40 . (canceled)

41 . (canceled)

42 . (canceled)

43 . (canceled)

44 . (canceled)

45 . (canceled)

46 . (canceled)

47 . (canceled)

48 . (canceled)

49 . (canceled)

50 . (canceled)

51 . A system, comprising:

a computer readable medium including, but not limited to, a computer program for use with a computer system and wherein the computer program includes a plurality of instructions including:

one or more instructions for selecting one or more computable epitopes;

one or more instructions for predicting at least one pattern change in the one or more computable epitopes;

one or more instructions for associating the at least one pattern change in the one or more computable epitopes with at least one outcome; and

one or more instructions for designating a course of action associated with the at least one pattern change in the one or more computable epitopes.

52 . (canceled)

53 . (canceled)

54 . (canceled)

55 . (canceled)

56 . A system, comprising:

circuitry for selecting one or more computable epitopes;

circuitry for predicting at least one pattern change in the one or more computable epitopes;

circuitry for associating the at least one pattern change in the one or more computable epitopes with at least one outcome; and

circuitry for designating a course of action associated with the at least one pattern change in the one or more computable epitopes.

57 . A system, comprising:

means for selecting one or more computable epitopes;

means for predicting at least one pattern change in the one or more computable epitopes;

means for associating the at least one pattern change in the one or more computable epitopes with at least one outcome; and

means for designating a course of action associated with the at least one pattern change in the one or more computable epitopes.